利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.047 秒)

    FENOFIBRATE FORMULATION WITH ENHANCED ORAL BIOAVAILABILITY
    51.
    发明申请
    FENOFIBRATE FORMULATION WITH ENHANCED ORAL BIOAVAILABILITY 审中-公开
    具有增强口腔生物利用度的FENOFIBRATE配方

    公开(公告)号：US20110160274A1

    公开(公告)日：2011-06-30

    申请号：US13002372

    申请日：2009-06-26

    申请人： Rajesh Jain ,  Sarabjit Singh ,  Naveen Jain ,  Shivanand Puthli

    发明人： Rajesh Jain ,  Sarabjit Singh ,  Naveen Jain ,  Shivanand Puthli

    IPC分类号： A61K31/40 ,  A61K31/216 ,  A61P3/10 ,  A61P9/00

    CPC分类号： A61K9/4858

    摘要： The present invention provides a formulation of fenofibrate with enhanced oral bioavailability, simplicity of design and manufacture and absence of food effect. The formulation comprises fenofibrate dissolved in a lipophilic surfactant, with a hydrophilic surfactant optionally added. The formulation can be effectively used in the management and treatment of conditions such as hypertriglyceridemia, hypercholesterolemia and mixed dyslipidemia, and can also be effective at lower doses as compared to commercially available products. The invention additionally relates to the process of manufacture of the formulation and to dosage forms comprising the same.

    摘要翻译： 本发明提供了非诺贝特配方，其具有增强的口服生物利用度，设计和制造的简单性和食物效果的不存在。 该制剂包含溶解在亲脂性表面活性剂中的非诺贝特，任选加入亲水性表面活性剂。 该制剂可以有效地用于治疗和治疗诸如高甘油三酯血症，高胆固醇血症和混合性血脂异常之类的病症，并且与可商购的产品相比也可以以较低的剂量有效。 本发明还涉及制剂的制备方法和包含其的剂型。

    INJECTABLE DEPOT COMPOSITIONS AND ITS PROCESS OF PREPARATION
    53.
    发明申请
    INJECTABLE DEPOT COMPOSITIONS AND ITS PROCESS OF PREPARATION 审中-公开
    可注射成分组合物及其制备方法

    公开(公告)号：US20100098735A1

    公开(公告)日：2010-04-22

    申请号：US12444257

    申请日：2007-10-03

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

    IPC分类号： A61K9/00 ,  A61K31/4196 ,  A61K31/18 ,  A61K9/14 ,  A61P35/00

    CPC分类号： A61K9/0024 ,  A61K9/06 ,  A61K9/1647

    摘要： Novel injectable compositions are provided comprising an active agent which is tamsulosin or letrozole or its pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof and one or more pharmaceutically acceptable excipient(s) wherein the compositions are preferably formulated as biodegradable microparticles or nanoparticles which can optionally be reconstituted with an aqueous, hydro-alcoholic or oily liquid vehicle prior to administration. The novel injectable compositions of the present invention preferably form a depot upon administration in vivo and are in the form of an in situ gelling composition or an implant composition which provides a prolonged release of tamsulosin or letrozole for extended periods of time. Also described are process for preparation of such novel compositions and method of using them.

    摘要翻译： 提供新的可注射组合物，其包含活性剂，其为坦索罗辛或来曲唑或其药学上可接受的盐，衍生物，异构体，多晶型物，溶剂合物，水合物，类似物，对映体，互变异构形式或其混合物，以及一种或多种药学上可接受的赋形剂，其中 组合物优选配制成可生物降解的微粒或纳米颗粒，其可以在施用前任选地用水性，水性醇或油性液体载体重构。 本发明的新型可注射组合物优选在体内施用时形成贮库，并且是呈现长时间释放坦索罗辛或来曲唑的原位胶凝组合物或植入物组合物的形式。 还描述了这种新型组合物的制备方法和使用它们的方法。

    INJECTABLE DEPOT COMPOSITIONS AND IT'S PROCESS OF PREPARATION
    54.
    发明申请
    INJECTABLE DEPOT COMPOSITIONS AND IT'S PROCESS OF PREPARATION 审中-公开
    注射剂组合物及其制备方法

    公开(公告)号：US20100015195A1

    公开(公告)日：2010-01-21

    申请号：US12444197

    申请日：2007-10-03

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

    IPC分类号： A61K31/496 ,  A61K31/4196 ,  A61K31/445 ,  A61K31/498 ,  A61K9/00 ,  A61K9/14 ,  A61P35/00

    CPC分类号： A61K9/0024 ,  A61K9/06 ,  A61K9/1647

    摘要： Novel injectable depot compositions are provided comprising at least one active agent(s) optionally with one or more pharmaceutically acceptable excipient(s) in the form of a multi-component system preferably comprising at least two components which when administered to a subject in need thereof forms an in situ gel depot or implant at the site of injection upon contact with body fluids. Also described are process for preparation of such compositions and method of using such compositions.

    摘要翻译： 提供了新的可注射贮库组合物，其包含至少一种活性剂，其任选地具有多组分体系形式的一种或多种药学上可接受的赋形剂，优选包含至少两种组分，当其施用于有需要的受试者时 在与体液接触时在注射部位形成原位凝胶储库或植入物。 还描述了制备这种组合物的方法和使用这种组合物的方法。

    Planar etching of dissimilar materials
    55.
    发明申请
    Planar etching of dissimilar materials 审中-公开
    平面蚀刻不同材料

    公开(公告)号：US20080113455A1

    公开(公告)日：2008-05-15

    申请号：US11823565

    申请日：2007-06-28

    申请人： Rajesh Jain ,  Tahir Malik ,  Vladimir Makarov

    发明人： Rajesh Jain ,  Tahir Malik ,  Vladimir Makarov

    IPC分类号： H01L21/306 ,  G05D9/00 ,  H01L21/02

    CPC分类号： H01L21/32136 ,  H01J37/3056 ,  H01J2237/3174 ,  H01L21/31116

    摘要： A method of planar etching of dissimilar materials with a Focused Ion Beam (FIB) system such as the OptiFIB manufactured by Credence Systems. The method includes adjusting the selectivity between the two materials, which varies when the ratio of the assisting chemistry pressure to the ion dose rate changes. This method can be used in such applications as FIB circuit edit, failure analysis, and cross sectioning.

    摘要翻译： 用聚焦离子束（FIB）系统（如Credence Systems制造的OptiFIB）对不同材料进行平面蚀刻的方法。 该方法包括调节两种材料之间的选择性，当辅助化学物质压力与离子剂量率的比率发生变化时，这种选择性会发生变化。 该方法可用于FIB电路编辑，故障分析和横截面等应用。

    Pharmaceutical compositions comprising an extract of Euphorbia prostrata
    56.
    发明授权
    Pharmaceutical compositions comprising an extract of Euphorbia prostrata 有权
    包含大戟提取物的药物组合物

    公开(公告)号：US07371412B2

    公开(公告)日：2008-05-13

    申请号：US10551797

    申请日：2004-12-31

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Aniruddha Datta

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Aniruddha Datta

    IPC分类号： A61K36/00

    CPC分类号： A61K36/47 ,  A61K36/185 ,  A61K36/48 ,  A61K2300/00

    摘要： The invention relates to novel compositions comprising of an extract of the plant Euphorbia prostrata, particularly with pharmaceutically acceptable carrier(s)/base(s), optionally with additional therapeutic agent(s) useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease, and the like. The novel compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings. Process for the preparation of such novel compositions comprising an extract of the plant Euphorbia prostrata and pharmaceutically acceptable carrier(s)/base(s) useful for the treatment of anorectal disease including hemorrhoids, and colonic diseases are also provided. The composition comprise of flavonoidal and phenolic constituents extracted from the plant Euphorbia prostrata that possess anti-inflammatory, analgesic, haemostatic and wound-healing properties.

    摘要翻译： 本发明涉及包含植物大戟提取物，特别是与药学上可接受的载体/碱的提取物的新型组合物，任选地可用于治疗肛门直肠疾病和结肠疾病的其它治疗剂，例如 痔疮，裂缝，裂缝，瘘，脓肿，炎症性肠病等。 该新型组合物具有控制哺乳动物，特别是人类的炎症，防止毛细血管出血和脆性的性质。 还提供了制备这种新型组合物的方法，该组合物包含植物大戟草提取物和可用于治疗包括痔疮和结肠疾病在内的肛门直肠疾病的药学上可接受的载体/碱基。 该组合物包含从具有抗炎，镇痛，止血和伤口愈合特性的植物大戟科提取的黄酮和酚成分。

    Oral pharmaceutical composition of a poorly water-soluble active agent
    57.
    发明申请
    Oral pharmaceutical composition of a poorly water-soluble active agent 审中-公开
    低水溶性活性剂的口服药物组合物

    公开(公告)号：US20070299054A1

    公开(公告)日：2007-12-27

    申请号：US11812763

    申请日：2007-06-21

    申请人： Rajesh Jain ,  Kour C. Jindal ,  Amarjit Singh ,  Munish Talwar ,  Henricus R.M. Gorissen

    发明人： Rajesh Jain ,  Kour C. Jindal ,  Amarjit Singh ,  Munish Talwar ,  Henricus R.M. Gorissen

    IPC分类号： A61K31/55 ,  A61K31/675

    CPC分类号： A61K9/2009 ,  A61K9/485

    摘要： The present invention relates to an improved oral pharmaceutical composition containing at least one poorly water soluble active agent, the active agent containing at least one of an endothelin conversion enzyme (ECE) inhibitor and a neutral endopeptidase (NEP) inhibitor in an amount greater than 10% w/w of the composition, and an alkali system comprising a mixture of at least two alkaline compounds in a ratio of from 1:20 to 20:1. The present invention also relates to an improved oral pharmaceutical composition containing, SLV-306 or at least one pharmaceutically acceptable salt, ester, hydrate, solvate, isomer or derivative thereof, as an active agent, and an alkali system in an amount greater than 10% w/w of the composition comprising a mixture of at least two alkaline compounds and optionally at least one pharmaceutically acceptable excipient. The present invention further relates to a process for preparation of such improved compositions and methods for treatment using such compositions.

    摘要翻译： 本发明涉及含有至少一种难溶于水的活性剂的改进的口服药物组合物，所述活性剂含有大于10的量的内皮素转化酶（ECE）抑制剂和中性肽链内切酶（NEP）抑制剂中的至少一种 ％w / w的组合物，以及包含比例为1:20至20:1的至少两种碱性化合物的混合物的碱系统。 本发明还涉及一种改进的口服药物组合物，其含有SLV-306或其至少一种药学上可接受的盐，酯，水合物，溶剂合物，异构体或衍生物作为活性剂，和大于10的量的碱系统 包含至少两种碱性化合物和任选的至少一种药学上可接受的赋形剂的混合物的组合物的％w / w。 本发明还涉及这种改进的组合物的制备方法和使用这种组合物的处理方法。

    Oral immediate release formulation of a poorly water-soluble active substance
    58.
    发明申请
    Oral immediate release formulation of a poorly water-soluble active substance 审中-公开
    低水溶性活性物质的口服立即释放制剂

    公开(公告)号：US20060159748A1

    公开(公告)日：2006-07-20

    申请号：US11311220

    申请日：2005-12-20

    申请人： Rajesh Jain ,  Sukhjeet Singh ,  Rohit Kumar ,  Marius De Winter

    发明人： Rajesh Jain ,  Sukhjeet Singh ,  Rohit Kumar ,  Marius De Winter

    IPC分类号： A61K31/55 ,  A61K9/20

    CPC分类号： A61K9/2077 ,  A61K31/55

    摘要： The invention is related to an oral immediate release formulation of Benzazepin-1-acetic acid derivatives comprising a) said active substance in an amount of up to 65% of the total weight of the formulation; b) at least 10% w/w an alkaline compound or a mixture of alkaline compounds; c) between 0.1 and 10% of one or more surfactants, and d) optionally comprises auxiliary materials an amount of between 1% and 45% of the total weight of the formulation.

    摘要翻译： 本发明涉及苯扎氮平-1-乙酸衍生物的口服立即释放制剂，其包含a）所述活性物质的量高达制剂总重量的65％; b）至少10％w / w的碱性化合物或碱性化合物的混合物; c）0.1至10％的一种或多种表面活性剂，和d）任选地包含占制剂总重量的1％至45％的量的辅助材料。